The agreement aims to provide manufacturing and clinical packaging technologies for companies that are developing plasmid DNA vaccines and other biologics.
As part of the new extension arrangement, Althea said it will provide additional capacity for small batch production and filling capabilities to customers in preclinical through phase III clinical trials. Baxter Healthcare Corporation and Baxter Pharmaceutical Solutions will continue to provide development services and clinical scale production support while also providing large batch production, packaging and filling services.
This ongoing agreement with Althea provides our customers with complementary contract services to Baxter’s offering, which includes: development and manufacturing of API, form/fill/finish into syringes, vials and cartridges, lyophilization and cytotoxics manufacturing in addition to our proprietary technologies, which includes Nanoedge dispersion and Promaxx microsphere formulation technologies and our enhanced packaging, said Joel Tune, general manager of Baxter’s BioPharma Solutions business.
